Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355148 | 0.94 | EPHX1 (0.57) | EPHX1NPSR1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL18352522 | 0.94 | EPHX1 (0.58) | EPHX1EPHX2RAB9ASMN1; SMN2NAAA | |
| SCHEMBL17550885 | 0.82 | EPHX1 (0.64) | EPHX1NPSR1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL2436673 | 0.81 | EPHX1 (0.59) | EPHX1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL18364177 | 0.81 | EPHX2 (0.59) | EPHX1EPHX2 | |
| SCHEMBL16092908 | 0.80 | L3MBTL1 (0.47) | EPHX1NPSR1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL18355260 | 0.79 | EPHX1 (0.41) | EPHX1KEAP1NFE2L2HCAR2NAAA | |
| SCHEMBL18364363 | 0.79 | EPHX2 (0.68) | EPHX1EPHX2 | |
| SCHEMBL18354919 | 0.79 | EPHX1 (0.41) | EPHX1NPSR1EPHX2RAB9ALMNA | |
| SCHEMBL18352143 | 0.78 | NPSR1 (0.47) | NPSR1EPHX2RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | EPHX1 2795/4885NPSR1 4344/4885EPHX2 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.